Alzheimer's disease

Alzheimer s disease (AD) is a neurodegenerative disease that robs the minds of our elderly population. Approximately one in every eight adults over the age of 65 and nearly half of those over 85 are afflicted with this disease. The aging population in developed societies will impose an ever increasi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Autor Principal: Lau, Lit-Fui
Outros autores: Brodney, Michael A. (Éditeur intellectuel), Lau, Lit-Fui, 19..- (Directeur de la publication), Brodney, Michael A., 19..- (Directeur de la publication)
Formato: Livre numérique
Idioma:Anglais
Publicado: Berlin, Heidelberg : Springer Berlin Heidelberg [20..].
Cham : Springer Nature
Edición:1st ed. 2008.
Series:Topics in Medicinal Chemistry 2
Acceso en liña:Accès sur la plateforme de l'éditeur
Accès sur la plateforme Istex
Accès Université d'Orléans
Accès INSA CVL
Nota: Archives Springer e-books (Licence nationale)
Archives Springer e-books (Licence nationale)
Autres localisations: Voir dans le Sudoc
Variante du titre:With contributions by numerous experts
Edition sous un autre format:• Alzheimer's Disease, Texte imprimé, 9783540742289
• Alzheimer's Disease, Texte imprimé, 9783642093548
• Alzheimer's Disease, Texte imprimé, 9783540842231
• Alzheimer's Disease, Texte imprimé, 9783540742289
LEADER 03821nam a22004097a 4500
001 940156
008 080505q2000 xx ||| |||| 00| 0 eng d
009 PPN123739497
020 |a 9783540742296 
041 0 |a eng 
082 |a 615.19 
100 1 |a Lau, Lit-Fui. 
240 1 0 |a With contributions by numerous experts 
245 1 0 |a Alzheimer's disease   |c edited by Lit-Fui Lau, Michael A. Brodney. 
250 |a 1st ed. 2008. 
260 |a Berlin, Heidelberg :  |b Springer Berlin Heidelberg. 
260 |a Cham :  |b Springer Nature,  |c [20..]. 
490 0 |a Topics in Medicinal Chemistry  |v 2  |x 1862-247X 
500 |a Archives Springer e-books (Licence nationale) 
500 |a Archives Springer e-books (Licence nationale) 
505 1 |a Therapeutic Approaches for the Treatment of Alzheimer's Disease: An Overview Cholinesterase Inhibitors Beyond Cholesterol: Statin Benefits in Alzheimer's Disease PPAR? Agonists for the Treatment of Alzheimer's Disease Metal Complexing Agents for the Treatment of Alzheimer's Disease GSK-3 Inhibitors for the Treatment of Alzheimer's Disease 
506 |a Accès en ligne pour les établissements français bénéficiaires des licences nationales 
506 |a Accès soumis à abonnement pour tout autre établissement 
506 |a Conditions particulières de réutilisation pour les bénéficiaires des licences nationales. https://www.licencesnationales.fr/springer-nature-ebooks-contrat-licence-ln-2017 
520 |a Alzheimer s disease (AD) is a neurodegenerative disease that robs the minds of our elderly population. Approximately one in every eight adults over the age of 65 and nearly half of those over 85 are afflicted with this disease. The aging population in developed societies will impose an ever increasing socioeconomic threat in the future. Current medicines for AD patients are mainly symptomatic treatments and a huge unmet medical need exists to slow the progression of this disease. A great deal of research has been dedicated to understanding the pathogenesis of AD from which comes many ideas for intervening with its progression. Some of these ideas have been fast-tracked to clinical trials due to the availability of medicines with proven clinical efficacies for other diseases (e.g. atorvastatin, simvastatin, rosiglitazone and clioquinol) while others represent novel chemical entities (e.g. glycogen synthase kinase-3 inhibitors). This volume will first review existing cholinesterase inhibitors prescribed for AD patients followed by some target mechanisms with ongoing clinical trials. It offers a glimpse of what our future medicine cabinets may look like for AD patients. It also provides an interesting read on why and how current medicines for other indications could potentially be used to treat AD 
700 1 |a Brodney, Michael A.  |4 edt 
700 1 |a Lau, Lit-Fui,  |d 19..-  |4 pbd 
700 1 |a Brodney, Michael A.,  |d 19..-  |4 pbd 
776 0 |t Alzheimer's Disease  |b Texte imprimé  |z 9783540742289 
776 0 |t Alzheimer's Disease  |b Texte imprimé  |z 9783642093548 
776 0 |t Alzheimer's Disease  |b Texte imprimé  |z 9783540842231 
776 0 |t Alzheimer's Disease  |b Texte imprimé  |z 9783540742289 
856 4 |q PDF  |u https://doi.org/10.1007/978-3-540-74229-6  |z Accès sur la plateforme de l'éditeur 
856 4 |u https://revue-sommaire.istex.fr/ark:/67375/8Q1-K0PFTH5R-B  |z Accès sur la plateforme Istex 
856 4 |5 452349901:747863954  |u https://ezproxy.univ-orleans.fr/login?url=https://dx.doi.org/10.1007/978-3-540-74229-6  |z Accès Université d'Orléans 
856 4 |5 180339901:750881518  |u https://ezproxy.insa-cvl.fr/login?qurl=https://dx.doi.org/10.1007/978-3-540-74229-6  |z Accès INSA CVL 
997 |0 940156  |1 Livre numérique  |a Ressource numérique  |b INSA  |b ENSA  |c 0/Bibliothèque numérique/  |c 1/Bibliothèque numérique/Autre ressource numérique/